弥合年龄差距研究:化疗对老年早期乳腺癌患者生活质量的影响
该前瞻性多中心观察研究纳入1520例≥70岁高危早期乳腺癌术后患者,其中24.7%接受化疗。化疗在6个月时对多个生活质量维度有显著负面影响,但到18-24个月时影响不再显著。
要点
- 化疗对老年早期乳腺癌患者生活质量在6个月时有显著负面影响。
- 这些负面影响在18-24个月时不再显著。
- 该结果有助于老年患者化疗决策。
核心结论
- 化疗对生活质量的负面影响在6个月时有临床和统计学意义,但到18个月时消退。
研究设计与样本
- 前瞻性、多中心、观察性研究,2013-2018年在56家英国医院开展,纳入≥70岁早期乳腺癌患者。
主要发现
- 376/1520(24.7%)患者接受化疗。
- 6个月时,化疗对EORTC-QLQ-C30的多个领域有显著负面影响,包括总体健康评分、躯体、角色、社会功能、认知、疲劳、恶心/呕吐、呼吸困难、食欲丧失、腹泻和便秘。
- 其他量表(EORTC-QLQ-BR23、EORTC-QLQ-ELD15和EQ-5D-5L)也记录到类似趋势。
- 在未匹配和匹配队列中,18-24个月时影响不再显著。
临床怎么用
- 向考虑化疗的老年早期乳腺癌患者说明:化疗对生活质量的负面影响在6个月时显著,但到18个月时消退。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Older patients with early breast cancer (EBC) derive modest survival benefit from chemotherapy but have increased toxicity risk. Data on the impact of chemotherapy for EBC on quality of life in older patients are limited, but this is a key determinant of treatment acceptance. We aimed to investigate its effect on quality of life in older patients enrolled in the Bridging the Age Gap study. MATERIALS AND METHODS: A prospective, multicentre, observational study of EBC patients ≥70 years old was conducted in 2013-2018 at 56 UK hospitals. Demographics, patient, tumour characteristics, treatments and adverse events were recorded. Quality of life was assessed using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires (EORTC-QLQ) C30, BR23 and ELD 15 plus the Euroqol-5D (eq-5d) over 24 months and analysed at each time point using baseline adjusted linear regression analysis and propensity score-matching. RESULTS: Three thousand and four hundred sixteen patients were enrolled in the study; 1520 patients undergoing surgery and who had high-risk EBC were included in this analysis. 376/1520 (24.7%) received chemotherapy. At 6 months, chemotherapy had a significant negative impact in several EORTC-QLQ-C30 domains, including global health score, physical, role, social functioning, cognition, fatigue, nausea/vomiting, dyspnoea, appetite loss, diarrhoea and constipation. Similar trends were documented on other scales (EORTC-QLQ-BR23, EORTC-QLQ-ELD15 and EQ-5D-5L). Its impact was no longer significant at 18-24 months in unmatched and matched cohorts. CONCLUSIONS: The negative impact of chemotherapy on quality-of-life is clinically and statistically significant at 6 months but resolves by 18 months, which is crucial to inform decision-making for older patients contemplating chemotherapy. TRIAL REGISTRATION NUMBER ISRCTN: 46099296.
引用
- Battisti NML, Reed MWR, Herbert E, et al. Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer. Eur J Cancer. 2020. PMID: 33373871. doi:10.1016/j.ejca.2020.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。